Fig 3.

In vivo efficacy of RBx 14255 in a hamster model of C. difficile infection. Hamsters were pretreated with 30 mg/kg of clindamycin subcutaneously on day −1 and infected orally with C. difficile on day 0. Hamsters were treated with RBx 14255 (50 mg/kg), metronidazole (150 mg/kg), and vancomycin (5 mg/kg) orally twice a day on day 1 until day 5 and observed for clinical signs of disease and mortality. All RBx 14255-treated animals showed extended survival compared to metronidazole-treated animals (P < 0.0001) and vancomycin-treated animals (P < 0.002).